Sign inJoin waitlistJoin the waitlist

Brent Rexer

Assistant Professor of Medicine, Division of Hematology Oncology · Vanderbilt Univ Sch of Med

Credentials: · · · · ·

History

Vanderbilt Univ Sch of Med
Present
Vanderbilt University Medical Center
Present

Vanderbilt University School of Medicine
2006–2009
Vanderbilt University School of Medicine
2003–2006
Vanderbilt University School of Medicine
1999–2003
Baylor University
1990–1994

Research

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Review · Breast Cancer Research · 2011 · 373 citations
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications
Review · Critical reviews in oncogenesis · 2012 · First of 2 authors · 278 citations
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Journal of the National Cancer Institute · 2020 · 132 citations

Carlos Arteaga
19 papers
Ingrid Mayer
5 papers
Melinda Sanders
5 papers
AW
Antonio Wolff
4 papers
IK
Ian Krop
4 papers
JE
Jeffrey Engelman
4 papers
Mothaffar Rimawi
4 papers
Anna Storniolo
3 papers
Ben Park
3 papers
Kent Osborne
3 papers
Matthew Goetz
3 papers
Rita Nanda
3 papers

Grants

SPORE in Breast Cancer
National Cancer Institute · P50
Project lead · $324.8K · Vanderbilt University Medical Center
2003–2025
Molecular Mechanisms of Resistance to HER2 Inhibitors in Breast Cancer
National Cancer Institute · K08
Contact PI · $815.4K · Vanderbilt University
2010–2015

Clinical trials

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
Principal investigator · Completed · Early phase 1
Vanderbilt-Ingram Cancer Center
2019–2024
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Principal investigator · Completed · Phase 1
Vanderbilt-Ingram Cancer Center
2017–2024
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Site PI · Recruiting
Natera, Inc.
2026–2037
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Site PI · Recruiting · Phase 1, Phase 2
SynDevRx, Inc.
2022–2027